Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by Thenorth1990on Jun 24, 2021 5:27pm
282 Views
Post# 33448315

Only 1 analyst

Only 1 analyst There is only analyst covering this, so the target prices you see on most platforms including wsj , market watch etc are all referring to the same analysis. I think the only realistic ones are those with a $1 , That's the one I see from Ibkr and webull , after a reverse split, Yes $5.50 . We might be up 150 % ytd, but our sp always has been this range of 20 to 24 cents. When they announced ph1 might happen by 2019 , the sp slowly and steadily rose to 38 then the trouble with biogen ph3 held them back . This is the best time to invest in this firm no doubt, but can we trust them with their pipeline and deadlines , big NO!! But I am 100% if sure I sell now I will regret big time later but also don't want to be over optimistic.
<< Previous
Bullboard Posts
Next >>